RT Journal Article T1 Metabolomic response of osteosarcoma cells to nanographene oxide-mediated hyperthermia. A1 Cicuéndez Maroto, Mónica A1 Flores, Joana A1 Oliveira, Helena A1 Portolés Pérez, María Teresa A1 Vallet Regí, María Dulce Nombre A1 Vila, Mercedes A1 Duarte, Lola F AB Nanographene oxide (nGO)-mediated hyperthermia has been increasingly investigated as a localized, minimally invasive anticancer therapeutic approach. Near InfraRed (NIR) light irradiation for inducing hyperthermia is particularly attractive, because biological systems mostly lack chromophores that absorb in this spectral window, facilitating the selective heating and destruction of cells which have internalized the NIR absorbing- nanomaterials. However, little is known about biological effects accompanying nGO-mediated hyperthermia at cellular and molecular levels. In this work, well-characterized pegylated nGO sheets with a hydrodynamic size of 300 nm were incubated with human Saos-2 osteosarcoma cells for 24 h and their internalization verified by flow cytometry and confocal microscopy. No effect on cell viability was observed after nGO uptake by Saos-2 cells. However, a proliferation delay was observed due to the presence of nGO sheets in the cytoplasm. 1H NMR metabolomics was employed to screen for changes in the metabolic profile of cells, as this could help to improve understanding of cellular responses to nanomaterials and provide new endpoint markers of effect. Cells inter- nalizing nGO sheets showed noticeable changes in several metabolites compared to control cells, including decreased levels of several amino acids, taurine and creatine and increased levels of phosphocholine and ur- idine/adenosine nucleotides. After NIR irradiation, cells showed decreases in glutamate and uridine nucleotides, together with increases in glycerophosphocholine and adenosine monophosphate. Overall, this study has shown that the cellular metabolome sensitively responded to nGO exposure and nGO-mediated hyperthermia and that NMR metabolomics is a powerful tool to investigate treatment responses. PB Elsevier SN 0928-4931 YR 2018 FD 2018-05-18 LK https://hdl.handle.net/20.500.14352/12187 UL https://hdl.handle.net/20.500.14352/12187 LA eng NO RESEARCHER ID U-1678-2017 (María Teresa Portolés Pérez)ORCID 0000-0002-9681-0184 (María Teresa Portolés Pérez)RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí) NO Unión Europea. H2020 NO Ministerio de Economía y Competitividad (MINECO) DS Docta Complutense RD 6 abr 2025